The MHRA is inviting the next generation of doctors to explore how genetics could improve prescribing and patient safety in the UK.
Similar Posts
Guidance: AI Airlock Phase 2 Cohort
Phase 2 of the Airlock will include seven additional technologies spanning AI-powered clinical note taking, advanced cancer diagnostics, eye disease detection tools, and obesity treatment support systems.
Government to align with European specifications on high risk in vitro diagnostic devices to reduce regulatory burden
The specifications will establish standards for high-risk diagnostic tests while creating consistency with European regulations
New MHRA-supported research reveals patterns of vaccine-derived poliovirus spread and implications for global eradication efforts
Study provides crucial insights for targeting rapid response strategies and improving polio surveillance worldwide
MHRA calls on public to report side effects and suspected fakes during #MedSafetyWeek
The tenth annual #MedSafetyWeek brings together more than 130 medicines regulators and health organisations across 117 countries to encourage people to report suspected side effects from medicines and device incidents.
Decentralised Manufacture: UK Guideline of Good Pharmacovigilance Practices
Guidance covering various aspects of pharmacovigilance for authorised and unauthorised medicinal products (Specials and the Early Access to Medicines Scheme (EAMS)).
Five non-executive directors reappointed to the Medicines and Healthcare products Regulatory Agency Board
Two board members have been reappointed for two years, while three others have had their term extended by a year.